The FDA recently released a new compounding guidance: **Temporary Policy for Compounding of Certain Drugs for Hospitalized Patients by Pharmacy Compounders not Registered as Outsourcing Facilities During the COVID-19 Public Health Emergency.** 

The link to this guidance is: <a href="https://bit.ly/CompoundingPolicy">https://bit.ly/CompoundingPolicy</a>

If a pharmacy permitted with the MS Board wishes to provide compounded medications per this guidance, please send an email with the name, address, and Board of Pharmacy Permit Number of your pharmacy along with the medication that you wish to provide to <a href="mailto:compliance@mbp.ms.gov">compliance@mbp.ms.gov</a>. Do not provide medications before informing the Board of your intent to compound per this guidance and approval email is received. Medications should come from the list in the guidance.

After approval, send the information below to <a href="mailto:compliance@mbp.ms.gov">compliance@mbp.ms.gov</a> each time you are providing compounded medications to a facility per this guidance:

- Name, address, and Board of Pharmacy permit number of your facility- Include DEA Registration number if a controlled substance
- Name, address, and Board of Pharmacy permit number of facilities receiving-Include DEA Registration if a controlled substance
- Date of transaction
- Name of medication(s)
- Quantity of medication(s)

(Essentially, this is a copy of the invoice that you must maintain a copy and provide a copy to receiving pharmacy.)

If there are any questions, please email <a href="mailto:compliance@mbp.ms.gov">compliance@mbp.ms.gov</a>